Clinical Trials

At eFFECTOR, our passion is using the best science to develop better medicines to treat cancer. An important part of developing new treatments is conducting clinical trials. eFFECTOR is currently recruiting patients to be part of clinical trials to test potential new products.

Now Enrolling

A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy that are experiencing Insufficient Response to Checkpoint Inhibitor Alone

Disease:
Non-small cell lung cancer, bladder cancer, head and neck cancer, hepatocellular cancer and others.

Active, not recruiting.

More Info Clinical Trial

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Disease:
Solid tumors with activating mutation, amplification or fusion of HER2, ERBB3, FGFR1, FGFR2 or an activating mutation in KRAS, pancreatic adenocarcinoma.

Actively recruiting.

More Info Clinical Trial